Author of

• 18975

  +

  P3.01 - Advanced NSCLC (ID 621)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 23862

    +

    P3.01-003 - Study of the Relationship between EGFR Mutation Status and Bone Metastasis in Advanced Lung Adenocarcinoma (ID 7427)

    09:30 - 09:30  |  Author(s): A. Yasheng
    • Abstract

    Background:
    To investigate the relationship between EGFR mutation status and bone metastasis in lung adenocarcinoma.
    
    Method:
    We collected the data of 331 patients with advanced lung adenocarcinoma, and the status of EGFR mutation was detected by RT-PCR. Follow-up these patients was performed.
    
    Result:
    331 cases of advanced lung adenocarcinoma, EGFR mutation rate was 52.2%. The incidence of bone metastases (54.9%) and brain metastases (29.4%) with EGFR mutant patients was higher than that wild type. Compared with the number of metastases, EGFR mutant bone metastases were more than 2 and more, and the proportion of wild type single-site metastasis was more. The median survival of bone metastases in advanced lung adenocarcinoma was 14.7 months. EGFR gene mutant group, bone metastasis group median survival in 18.2 months, no bone metastasis group median survival in 21.8 months. In the wild-type group, the median survival of the bone metastases group was 11.5 months, and the median survival in the non-bone metastases group was 15.5 months.
    
    Conclusion:
    EGFR mutations in patients with advanced lung adenocarcinoma are more likely to develop bone metastasis and brain metastasis.